Method of treating androgen independent prostate cancer

Abstract

The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.

1 . A method of treating advanced stage prostate cancer, the method comprising administering a compound to a patient in need thereof, wherein the prostate cancer is hormone refractory and/or metastatic and the compound is selected from the group consisting of: 
     
       
         
         
             
             
         
       
     
     and the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells. 
   
   
       2 . The method of  claim 1 , wherein the prostate cancer is androgen independent and metastatic prostate cancer and the compound is administered in a pharmaceutical composition comprising a pharmaceutical acceptable carrier. 
   
   
       3 . The method of  claim 1 , wherein the compound is in an amount to induce apoptosis of androgen independent cancer cells. 
   
   
       4 . The method of  claim 1 , wherein the patient is human. 
   
   
       5 . The method of  claim 4 , wherein the compound is in an amount sufficient to inhibit at least 30% of invasive cells. 
   
   
       6 . The method of  claim 5 , wherein at least 60% of the invasive cells are inhibited. 
   
   
       7 . The method of  claim 1 , wherein the compound is administered in combination with paclitaxel. 
   
   
       8 . The method of  claim 1 , wherein the compound is administered in combination with dexamethasone. 
   
   
       9 . The method of  claim 1 , wherein the compound is administered in combination with a chemotherapeutic agent, a protein kinase inhibitor, a topoisomerase inhibitor, a mitotic kinesin inhibitor, a histone deacetylase inhibitor, a mTOR inhibitor, a growth factor inhibitor, a growth factor receptor inhibitor, a transcriptional factor inhibitor, an anticancer monoclonal antibody, and/or glucocorticoid hormones. 
   
   
       10 . The method of  claim 9 , wherein the chemotherapeutic agent is selected from the group consisting of: an alkylating agents, anti-metabolitic agents, antibiotics, anti-tubule agents, and anti-hormonal agents. 
   
   
       11 . The method of  claim 9 , wherein the protein kinase inhibitor inhibits at least one of the following: cyclin-dependent kinases, tyrosine kinases, phosphoinositide 3-kinase PI3K/AKT, protein kinase C, casein kinases, MAP kinases, or Src kinases. 
   
   
       12 . The method of  claim 1 , wherein the compound is administered orally. 
   
   
       13 . The method of  claim 1 , wherein the compound is administered parenterally. 
   
   
       14 . The method of  claim 13 , wherein the compound is administered subcutaneously, intravenously, intramuscularly, or intra-arterially. 
   
   
       15 . The method of  claim 14 , wherein the compound is administered to a human patient, in an amount of about 0.5 mg to 5 mg per kilogram of body weight. 
   
   
       16 . The method of  claim 1 , wherein compound is in a dosage unit forms containing between from about 10 mg to about 240 mg of the compound per day. 
   
   
       17 . A method of treating advanced stage prostate cancer, the method comprising administering to a patient having hormone refractory and/or metastatic prostate cancer a compound selected from the group consisting of: N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; or N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone, wherein the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells. 
   
   
       18 . The method of  claim 17 , wherein the compound is N-methyl-Δ3,3′-dihydroindole-2,2′ diketone. 
   
   
       19 . The method of  claim 18 , wherein the compound is N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone. 
   
   
       20 . The method of  claim 18 , wherein the compound is N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone.